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Abstract
Background: Cytochrome P450 1B1 (CYP1B1) has been shown to be up-regulated in many types of cancer including
renal cell carcinoma (RCC). Several reports have shown that CYP1B1 can influence the regulation of tumor development;
however, its role in RCC has not been well investigated. The aim of the present study was to determine the functional
effects of CYP1B1 gene on tumorigenesis in RCC.
Methods: Expression of CYP1B1 was determined in RCC cell lines, and tissue microarrays of 96 RCC and 25 normal
tissues. To determine the biological significance of CYP1B1 in RCC progression, we silenced the gene in Caki-1 and
769-P cells by RNA interference and performed various functional analyses.
Results: First, we confirmed that CYP1B1 protein expression was significantly higher in RCC cell lines compared to
normal kidney tissue. This trend was also observed in RCC samples (p < 0.01). Interestingly, CYP1B1 expression was
associated with tumor grade and stage. Next, we silenced the gene in Caki-1 and 769-P cells by RNA interference and
performed various functional analyses to determine the biological significance of CYP1B1 in RCC progression. Inhibition
of CYP1B1 expression resulted in decreased cell proliferation, migration and invasion of RCC cells. In addition, reduction
of CYP1B1 induced cellular apoptosis in Caki-1. We also found that these anti-tumor effects on RCC cells caused by
CYP1B1 depletion may be due to alteration of CDC20 and DAPK1 expression based on gene microarray and confirmed
by real-time PCR. Interestingly, CYP1B1 expression was associated with CDC20 and DAPK1 expression in clinical samples.
Conclusions: CYP1B1 may promote RCC development by inducing CDC20 expression and inhibiting apoptosis through
the down-regulation of DAPK1. Our results demonstrate that CYP1B1 can be a potential tumor biomarker and a target
for anticancer therapy in RCC.
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Background
In 2014 kidney cancer affected nearly 63,920 people with
an estimated 13,860 cancer related deaths in the United
States [1]. Among the various forms of kidney cancers,
renal cell carcinoma (RCC) is the most common,
attributing about 85 % [2]. Recent advances in imaging
technology and surgical techniques have contributed to
the improvement of oncologic outcomes for patients
with RCC. However, management of advanced RCC re-
mains an extraordinary challenge because of limited
therapeutic options and poor prognosis. Indeed, the 5-
year survival rate for RCC patients with metastasis is less
than 10 % [3]. In addition, about 30 % of localized RCC
patients experience recurrence and/or metastases after
curative radical surgery [4]. Thus, an increased under-
standing of the molecular basis of renal carcinogenesis
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may contribute to the development of better therapeutic
and diagnostic strategies for the disease.
Cytochrome P450 1B1 (CYP1B1) belongs to the cyto-
chrome P450 superfamily involved in the metabolism of
a diverse range of endogenous and xenobiotic com-
pounds including many carcinogens [5, 6]. CYP1B1 pro-
duces 4-hydroxy estrogens via hydroxylation of the
parent estrogen [7], which has been postulated to play a
major role in carcinogenesis by inducing DNA damage,
mutation, and depurination [8]. Indeed, previous studies
have demonstrated that CYP1B1 inhibition could prevent
endometrial and head and neck carcinogenesis [9, 10]. Al-
though CYP1B1 is expressed in normal tissues, it is
expressed at much higher levels in many malignancies in-
cluding RCC [11, 12]. In addition, elevated CYP1B1 en-
zymatic activity was found in RCC [13] despite the
tumorigenicity of CYP1B1 in RCC has not been elucidated.
Dysregulated cellular proliferation is one of the most
important factors that lead to tumorgenesis. In mitosis
phase, the progression of the cell cycle is tightly regu-
lated by the anaphase-promoting complex/cyclosome
(APC/C), which is a downstream target of the mitotic
spindle assembly checkpoint. The cell division cycle 20
homolog (CDC20), an essential regulator of cell division,
complexes with APC/C which leads to the initiation of
anaphase in early mitosis [14]. Therefore dysregulation of
CDC20 may play important roles in cell growth and
tumorigenesis. Recent studies have shown that CDC20
overexpression might be associated with an inappropri-
ately functioning spindle assembly checkpoint, resulting in
aneuploidy [15, 16]. Indeed, CDC20 overexpression has
been linked to poor prognosis in lung [17], colon [18],
bladder [19], gastric [20] and breast [21] carcinomas.
Apoptosis, a genetically controlled mechanism of cell
death, is involved in embryonic development, tissue
homeostasis and many diseases including cancer [22].
An imbalance between pro-apoptotic and anti-apoptotic
factors induces an abnormal pattern of cell death. The
death-associated protein kinase-1 (DAPK1), a serine/
threonine kinase, is a p53 target gene and its activation
may lead to apoptosis through activation of p53 [23, 24].
DAPK1 is widely expressed in normal tissues, while it is
down-regulated in various malignancies [25–28].
Interestingly, a recent study has demonstrated that at-
tenuation of CYP1B1 expression has anti-proliferative
and pro-apoptotic effects on endometrial cancer [9]. In
light of this, we hypothesized that CYP1B1 may play a
key role in renal carcinogenesis. The aim of this study
was to identify the role of CYP1B1 in the pathogenesis
of RCC. In this study, we confirmed that CYP1B1 ex-
pression was up-regulated in both RCC cells and sam-
ples. To validate the functional significance of CYP1B1
overexpression, we depleted the gene in RCC cell lines
by RNA interference and performed functional analysis.
We also identified several key genes of the pathway in-
volved in transformation and tumorigenesis based on
gene microarray data. Finally, we found that CDC20 and
DAPK1 are potentially regulated by CYP1B1.
Methods
Normal kidney sample and tissue microarray
Fresh frozen normal kidney tissue was purchased from
BioServe (Beltsville, MD, USA). In total, 96 primary
RCC comprised of 31 specimens from tissue microarray
(TMA) KD951, 40 specimens from TMA KD485 (both
acquired from US Biomax, Rockville, MD, USA), and 25
specimens from TMA CT565907 (ORIGENE, Rockville,
MD, USA) were evaluated. Also, twenty-five normal kid-
ney specimens were obtained from these 3 TMAs. Median
patient age at surgery was 57 years old. Of the 96 RCC
specimens, 83 were clear cell carcinoma and the remaining
13 specimens were non-clear cell carcinoma (3 papillary
carcinoma, 3 chromophobe carcinoma, 3 sarcomatoid car-
cinoma, 2 granular carcinoma and 2 collecting duct carcin-
oma). Forty-seven (49.0 %) patients had Fuhrman grade 1
or 2, 15 (15.6 %) were grade 3 or 4, and the remaining 34
(35.4 %) were unknown. Forty (41.7 %) patients were stage
I, 16 (16.7 %) patients stage II, 7 (7.3 %) stage III, 2 (2.1 %)
stage IV, and the remaining 31 (32.2 %) were unknown.
Cell lines and reagents
Renal cancer cell lines, Caki-1, Caki-2, A498, ACHN,
786-O and 769-P were obtained from the American
Type Culture Collection (Manassas, VA, USA). McCoy’s
5A, MEM Eagle’s BSS (EMEM), RPMI 1640, Opti-MEM
and penicillin/streptomycin mixture were obtained from
the UCSF Cell Culture Facility (San Francisco, CA,
USA). Fetal bovine serum (FBS) was a product of At-
lanta Biologicals (Lawrenceville, GA, USA).
Cell culture
Caki-1 and Caki-2 cells were cultured in McCoy’s 5A,
and A498 and ACHN cells were maintained in EMEM
medium while 786-O and 769-P cells were cultured in
RPMI 1640 medium. All culture medium contained
10 % FBS and 100 μg/ml penicillin/streptomycin. All cell
lines were maintained at 37 °C in a humidified atmos-
phere composed of 5 % CO2 and 95 % air.
Knockdown of CYP1B1 in Caki-1 and 769-P cells
Oligonucleotides siRNA against human CYP1B1 and mis-
match control oligonucleotides were purchased from Life
technologies. For inhibition of CYP1B1, 5 μl of siRNA oli-
gonucleotides (siRNA-CYP1B1 or siRNA-control) and 5 μl
of lipofectamine RNAiMAX reagent (Invitrogen-Life Tech-
nologies Inc., Carlsbad, CA, USA) were separately diluted
with 250 μl of Opti-MEM (Gibco, Carlsbad, CA, USA).
Cells were then transfected with lipofectamine + siRNA-
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CYP1B1, lipofectamine + siRNA-control, or left untrans-
fected. Transfection was terminated after 5 h by aspirating
the transfection medium and adding fresh RPMI 1640 con-
taining 10 % FBS. Non-adherent cells were washed off and
the remaining cells were incubated at 37 °C.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from cultured cells using
RNeasy Mini Kit (Qiagen) and was converted into cDNA
by using an iScriptTM cDNA Synthesis Kit (BIO-RAD)
according to the manufacturer’s instruction. To as-
sess gene expression, cDNA was amplified with the
TaqMan® Gene Expression Assays and TaqMan® Fast
Universal PCR Master Mix using the 7500 Fast Real-
Time PCR System. The target genes and their Assay
ID were as follows: CYP1B1 (HSpp16383_m1), DKC1
(Hs00154737_m1), OCLN (Hs00170162_m1), FASLG
(Hs00181225_m1), MKI67 (Hs01032443_m1), LPL
(Hs00173425_m1), CA9 (Hs00154208_m1), CDC20
(Hs00426680_mH), TP73 (Hs00390315_m1), BCL2A1
(Hs00187845_m1), LTA (Hs04188773_g1), DAPK1
(Hs00234489_m1), BIRC5 (Hs04194391_sH) and
GAPDH (Hs03929097_g1). The relative level was cal-
culated by the comparative Ct method (ΔΔCt) using
the 7500 Fast System Sequence Detection Software
(Applied Biosystems).
PCR assay of apoptosis and cancer pathways
cDNAs were evaluated for genes using the RT2 ProfilerTM
PCR Array PAHS-012ZC (Human Apoptosis PCR Array)
and the RT2 ProfilerTM PCR Array PAHS-033ZC (Human
Cancer Pathway FinderTM ) on the ABI Fast 7900 real-
time PCR system with RT2 Real-time SYBR Green PCR
master mix according to the manufacturer’s protocol.
MTS assay
Cells were plated in triplicate in 96-well microplates at a
density of 3 × 103 cells per well. The number of viable cells
was determined by adding 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium-based CellTiter 96 Aqueous One Solution
Reagent (Promega, Madison, WI) to each well and meas-
uring the absorbance at 490 nm on SPECTRA MAX 190
plate reader (Molecular Devices, Sunnyvale, CA, USA).
Migration and invasion assay
Cell migration was evaluated by a wound-healing assay.
Cells were plated in six-well dishes and the cell monolayers
were scraped using a P-20 micropipette tip. Wound closure
was monitored and the percent closure was measured. A
cell invasion assay was carried out using modified Boyden
Chambers consisting of transwell-precoated Matrigel mem-
brane filter inserts with eight micro pores in 24-well tissue
culture plates (BD Biosciences, Bedford, MA, USA). Cells
were re-suspended in culture medium without FBS and
placed in the upper chamber in triplicate. After 48 h incu-
bation at 37 °C, cells migrating through the membrane
were stained. The results were expressed as invaded cells
quantified at OD 560 nm.
Apoptosis assay
Fluorescence-activated cell-sorting (FACS) analysis for
apoptosis was done 48 h post-transfection, using an
annexin V-fluorescein isothiocyanate (FITC)/7-amino-ac-
tinomycin D (7-AAD) staining system obtained from BD
Biosciences (San Diego, CA, USA) and a Cell Lab Quan-
taTM SC MPL (Beckman Coulter, Fullerton, CA, USA).
Cells were stained with annexin V-FITC only (early apop-
totic) or both annexin V-FITC and 7-AAD (late apoptotic)
and considered to be total apoptotic cell fractions.
Western analyses
Normal kidney tissue and whole cell extracts were pre-
pared using radioimmunoprecipitation assay buffer
(RIPA; Thermo Scientific, Rockford, IL, USA) containing
protease inhibitor cocktail (Roche Diagnostics, Basel,
Switzerland). Protein quantification was done using a
BCA protein assay kit (Pierce) according to the manu-
facturer’s instructions. Total cell protein (15–20 μg) was
used for Western blotting. Samples were run on the
polyacrylamide gels and then transferred to PVDF mem-
branes. The membranes were immersed in 3 % skim
milk in antibody against CYP1B1 (#ab32649, Abcam,
Cambridge, MA, USA), CDC20 (#4823, Cell Signaling
Technology), DAPK1 (#3008, Cell Signaling Technology)
and GAPDH (#sc-32233, Santa Cruz) overnight at 4 °C.
Blots were washed in TBS containing 0.1 % Tween20
and labeled with horseradish peroxidase conjugated sec-
ondary anti-rabbit antibody (Cell Signaling Technology).
Specific complexes were visualized with an enhanced
chemiluminescence (ECL) detection system (GE Health-
care, Little Chalfont, UK) using the Chemidoc imaging
system (Bio Rad, CA, USA). Protein expression levels
were expressed relative to GAPDH.
Immunohistochemical analyses
Immunostaining of CYP1B1, CDC20 and DAPK1 were
performed on TMA slides using UltraVision Detection
System (Thermo Scientific) according to the manufac-
ture’s instruction, and 2 TMA slides were evaluated for
each antibody. After 12 h incubation with rabbit poly-
clonal antibody for CYP1B1 (1:1500, #ab32649, Abcam),
CDC20 (1:100, #ab86104, Abcam) and DAPK1 (1:250,
#ab109382, Abcam), 3, 3'-diaminobenzidine (DAB) was
added as chromogen followed by counterstaining with
hematoxylin. The degree of immunostaining was evalu-
ated by two independent observers who were blind to
the clinical data of the TMAs. For CYP1B1, cytoplasmic
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expression was analyzed by the intensity of positive cells
using Image J software (http://rsb.info.nih.gov/ij) and
was ranked on an overall scale from 0 to 3; with 0 indi-
cating the absence of staining; 1, weak staining; 2, mod-
erate staining; and 3, strong staining [12]. CDC20 and
DAPK were scored by multiplication of the percentage
of positively stained tumor cells and staining intensity
according to previous studies [17, 18, 28]. Briefly, the
percentage of positive cells was scored as: 0, 0 %; 1+, 1–
10 %; 2+, 11–50 %; or 3+, 51–100 %. The intensity of
nuclear staining and/or cytoplasmic staining was scored
as follows: grade 0, negative; 1+, weakly positive; 2+,
moderately positive; or 3+, strongly positive. The two
scores were then multiplied to calculate the final score
(range from 0 to 9).
Statistical analysis
Values are presented as the mean ± standard error mean
based on results obtained from at least three independent
experiments. All data were analyzed by the StatView ver-
sion 5 statistical software (SAS Institute, Inc., Cary, NC).
The relationship between two variables and the numerical
values were analyzed using the two-tailed unpaired Stu-
dent’s t-test. Chi-square test was used for analyzing the
correlation between clinicopathologic parameters and
CYP1B1 expression. A p-value of less than 0.05 was con-
sidered to be statistically significant.
Ethics statement
All samples obtained with informed consent according to
US federal law were purchased commercially and at the la-
boratory in San Francisco, specimens and de-identified
patient data were used for analysis. This study was
approved by the Clinical Research Office of the San
Francisco Veterans Affairs Medical Center and the In-
stitutional Review Board (study number 10–03240) of
the University of California at San Francisco.
Fig. 1 CYP1B1 expression in RCC cell lines and tissues. a Representative immunoblot displaying CYP1B1 expression in normal kidney (NK) sample,
Caki-1, Caki-2, A498, ACHN, 786-O and 769-P. CYP1B1 protein was up-regulated in RCC cell lines in comparison with that of NK. b Representative
immunostaining of CYP1B1 in clinical sample obtained from tissue microarray. (a) Weak cytoplastic staining of CYP1B1 was observed in the normal renal
tubules. (b) Strong cytoplasmic staining of CYP1B1 was observed in clear cell RCC tumors. (c) CYP1B1 overexpression was also observed in chromophobe
RCC tumors. (d) CYP1B1 staining score in clinical samples. CYP1B1 protein expression in RCC samples was significantly higher than that of normal kidney
tissues . **, P< 0.01
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Results
CYP1B1 is up-regulated in RCC cell lines and RCC tissues
To determine CYP1B1 protein expression, Western ana-
lysis was performed using normal kidney tissue, Caki-1,
Caki-2, A498, ACHN, 786-O, and 769-P cells. CYP1B1 pro-
tein expression was significantly up-regulated in most RCC
cell lines compared with normal kidney (Fig. 1a). Next,
RCC TMA consisting of 96 cases of primary RCC was im-
munostained with CYP1B1 antibody. While CYP1B1 ex-
pression was weak or not detected in most of the normal
kidney tissues, the majority of RCC samples showed mod-
erate or strong CYP1B1 immunoreactivity with an average
staining score of 1.84 ± 0.10 (versus 1.16 ± 0.21 in normal
kidney tissues) (p < 0.01; Fig. 1b).
The clinicopathological status of the 96 RCC samples
is shown in Table 1. RCC were classified into 2 groups
according to CYP1B1 staining score; High (2–3) and
Low (0–1). Increased expression of CYP1B1 was corre-
lated with high grade or high stage disease, with a trend
toward statistical significance (P = 0.0875, P = 0.0692, re-
spectively). However, there were no significant
differences for age, gender, histological type, lymph node
and systematic metastasis between the groups.
Attenuation of CYP1B1 expression inhibits renal cancer
cell viability, migration, and invasion
CYP1B1 levels were increased in RCC and thus, the
functional significance of this gene were explored. This
was done by examining whether reduction of CYP1B1 ex-
pression has an effect on cell viability, migration, or inva-
sion properties of RCC cell lines. After transfection with
two different CYP1B1 siRNAs, significant reduction of
CYP1B1 mRNA and proteins were detected in both Caki-
1 and 769-P cells (Fig. 2a). Cell proliferation (Fig. 2b) and
wound healing assays (Fig. 2c) demonstrated significant
inhibition in CYP1B1 transfectants in both Caki-1 and
769-P cells compared to the control siRNA transfectants.
Matrigel invasion assay also showed that the number of
invaded cells was significantly decreased in CYP1B1 trans-
fectants compared with their control counterparts after
24 h (Fig. 2d). These results suggest that CYP1B1 plays an
important role in RCC progression.
CYP1B1 influences cellular apoptosis in RCC cells
Since attenuation of CYP1B1 expression significantly
inhibited cell growth and progression of RCC cells, we
hypothesized that its expression may induce apoptosis.
Apoptosis was examined in control siRNA-treated cells or
CYP1B1 siRNA-treated cells. Results of apoptosis assay in
Caki-1 and 769-P cells done 48 h post-transfection are
shown in Fig. 3. In Caki-1 cells, the apoptotic and early
apoptotic fractions (upper right and lower right in the
quadrant images, respectively) were significantly greater in
CYP1B1 -depleted cells (2.88 % + 5.23 %) compared to con-
trol cells (0.33 % + 1.36 %) (p < 0.05; Fig. 3a). In contrast,
these differences were not seen in 769-P cells (Fig. 3b).
CYP1B1 regulates the expression of CDC20 and DAPK1 in
RCC cell lines
To further understand the precise mechanism of the anti-
tumor effect on RCC cells induced by CYP1B1 knockdown,
we looked for changes in gene expression in CYP1B1
siRNA-treated and NS siRNA-treated control cells using
the Human Cancer Pathway RT2 ProfilerTM PCR Array
and the Human Apoptosis RT2 ProfilerTM PCR Array.
From the cancer pathway-related genes analyzed, eight
were down-regulated ~ 2- to 5- fold after CYP1B1 depletion
and among them, CDC20 was the greatest (Table 2). To
verify array data, we performed real-time PCR using Taq-
man probes. Consistently, a robust decrease of CDC20
mRNA expression was detected in CYP1B1 siRNA-treated
Caki-1 (6.1- fold) and 769-P (2.2- fold) (Fig. 4a). However, a
significant decrease of DKC1 (Dyskeratosis congenita1),
OCLN (Occuludin), and MIK67 (Antigen identified by
monoclonal antibody Ki-67) expression were seen in only
Table 1 CYP1B1 expression in relation to clinicopathological
findings
CYP1B1 staining score
Variables Low (n = 34) High (n = 62) P value
Median age (yrs) 58 57 0.2264
Gender
male 24 (70.6 %) 42 (67.7 %) 0.7735
female 10 (29.4 %) 20 (32.3 %)
Histology
clear cell 30 (88.2 %) 53 (85.5 %) 0.7063
non-clear cell 4 (11.8 %) 9 (14.5 %)
Fuhrman grade 0.0875
1–2 21 (61.7 %) 26 (41.9 %)
3–4 3 (8.9 %) 12 (19.4 %)
unknown 10 (29.4 %) 24 (38.7 %)
Stage 0.0692
I–II 24 (70.6 %) 32 (51.6 %)
III–IV 1 (2.9 %) 8 (12.9 %)
unknown 9 (26.5 %) 22 (35.5 %)
Lymph node metastasis 0.5085
negative 23 (67.7 %) 32 (51.6 %)
positive 1 (2.9 %) 3 (4.8 %)
unknown 10 (29.4 %) 27 (43.6 %)
Systematic metastasis 0.2180
negative 25 (73.5 %) 37 (59.7 %)
positive 2 (5.9 %) 8 (12.9 %)
unknown 6 (17.6 %) 17 (27.4 %)
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Caki-1 cells (Fig. 4a). We also examined the protein expres-
sion of CDC20 to identify the association with their mRNA
expression levels. As shown by Western blotting, CDC20
protein levels were significantly decreased in CYP1B1
siRNA-treated cells compared with NS siRNA-treated con-
trol cells (Fig. 4c). These results indicate that CDC20 is po-
tentially regulated by CYP1B1 in RCC.
Table 2 displays genes that were up-regulated and
down-regulated 2 or greater due to CYP1B1 knockdown
in apoptosis-related gene array analyses. Among 4 up-
regulated genes, only DAPK1 was found to be signifi-
cantly increased in both Caki-1 (1.6- fold) and 769-P
(1.3- fold) cells by real-time PCR (Fig. 4b). As shown in
Fig. 4c, an increase in DAPK1 protein was also found in
A
C
Caki-1
769-P
B
Caki-1
769-P
Caki-1
769-P
D
Caki-1
769-P
Fig. 2 Effect of CYP1B1 knockdown on cell proliferation, migration and invasion in RCC cell lines. a Knockdown of CYP1B1 levels in RCC cell lines
(Caki-1 and 769-P) were determined by real time RT-PCR and Western immunoblot analysis at 48 h after transfection with two different CYP1B1
siRNAs. b Cell viability was analyzed by the MTS cell proliferation assay 0, 24, 48 and 72 h after siRNA treatment. Attenuation of CYP1B1 significantly
inhibited cell viability in both cell lines. *, P < 0.05. **, P < 0.01.***, P < 0.001. c Representative images of wound healing assay. After siRNA transfection
for 48 h, a wound was formed by scraping and closure of wound measured after 24 h. Attenuation of CYP1B1 significantly inhibited cell migration. **,
P < 0.01.***, P < 0.001. d Representative images of invasion assay. Down-regulation of CY1B1 significantly decreases cell invasion. ***, P < 0.001
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both CYP1B1 siRNA-treated RCC cells. Though TP73
(Tumor protein p73) was observed to be most increased
by array analyses, its up-regulation was not confirmed in
Caki-1 by real-time PCR (Fig. 4b). Among 15 down-
regulated genes, BIRC5 (Baculoviral IAP repeat containing
5) was observed to be the lowest. However, a significant
decrease of BIRC5 mRNA expression was detected
only in CYP1B1 siRNA-treated Caki-1 (Fig. 4b). Thus,
these data indicate that the attenuation of CYP1B1
expression caused induction of DAPK1 and could lead
to apoptosis in RCC.
CYP1B1 expression is associated with CDC20 and DAPK1
expression in clinical samples
To validate the correlation between CYP1B1 expression
and CDC20 or DAPK1 expression, we performed immu-
nohistochemical studies using clinical samples. Case speci-
mens were grouped as Low or High CYP1B1 expression
categories as previously determined (Table 1). Representa-
tive CDC20 and DAPK1 immunostaining pattern are
shown in Fig. 5a. RCC samples showed a higher level of
CDC20 expression in comparison with normal kidney
specimens (Fig. 5b). In addition, the High CYP1B1 group
in RCC showed higher CDC20 expression than Low
CYP1B1 group, though the difference did not reach statis-
tical significance (Fig. 5a, b). As for DAPK1, strong cyto-
plasmic staining was more common in the normal kidney
samples than in the RCC tissues (Fig. 5a, b). Moreover,
RCC samples with Low CYP1B1 expression had a signifi-
cantly higher level of DAPK1 expression as compared to
those with High CYP1B1 expression (p < 0.01; Fig. 5a, b).
Discussion
It is recognized that CYP1B1 is up-regulated and plays an
essential role in carcinogenesis in several types of cancers
[9–11]. CYP1B1 catalyzes the hydroxylation of estrogens to
A
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1.36±0.52
0.33±0.12
5.23±0.40
2.88±0.11
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4.69±0.26
0.12±0.02
3.78±0.13
apoptosis
early apoptosis 
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early apoptosis 
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early apoptosis 0.25±0.01
Control siRNA #1
Caki-1 (48hr)
769-P (48hr)
B
0
2
4
6
8
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*
0
2
4
6
8
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to
si
s
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to
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s
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Fig. 3 Effect of CYP1B1 knockdown on apoptosis. Apoptosis assays with Caki-1 (a) and 769-P (b) cells were done 48 h post siRNA transfection.
Representative biparametric histogram showing cell population in early (bottom right quadrant) and late (top right quadrant) apoptotic and viable
(bottom left quadrant) states. The bar chart indicates the ratio of apoptotic cell fractions (early plus apoptotic cells) in CYP1B1 transfectants compared
with controls. Apoptotic cell fractions are expressed as relative value composed to the average expression of control siRNA transfectant. *, P < 0.05
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4-hydroxy-estrogens as well as convert polycyclic aromatic
hydrocarbons to mutagenic forms that play a causative role
in the carcinogenesis process [8, 29]. When 4-hydroxy-
estradiol was injected into animals, tumors were formed in
the kidneys [30, 31]. Therefore, it is not surprising that
CYP1B1 is actively involved in RCC. Here, we investigated
the effects of CYP1B1 in renal carcinogenesis by perform-
ing functional assays and gene microarray analyses.
CYP1B1 is expressed at high levels and its enzyme activ-
ity is significantly elevated in RCC [11–13]. In addition, its
overexpression contributes to the decreased sensitivity to
anticancer drugs, such as paclitaxel and docetaxel [32, 33].
Recently, we demonstrated that CYP1B1 up-regulation
could induce docetaxel resistance in RCC cells [12]. In this
report, we confirmed that CYP1B1 protein expression was
up-regulated in most RCC cell lines. Likewise, levels of
immunoreactive protein of CYP1B1 were found to be sig-
nificantly higher in clinical RCC tissues than normal kid-
ney tissues. Next, we examined the association between
CYP1B1 expression and clinicopathological findings in
RCC samples. Importantly, CYP1B1 over-expression was
correlated with high grade and advanced stage, though it
did not reach statistical significance. Thus, CYP1B1 is
demonstrated to have a potential prognostic and diagnos-
tic value in RCC.
Attenuation of CYP1B1 expression has been found to
decrease the proliferative activity, cell migration capabil-
ity and invasiveness of endometrial and head and neck
cancer cell lines [9, 10]. In our present study, CYP1B1
depletion also strongly inhibited these activities in RCC
cell lines. Aberration on the cell cycle is a well-known
mechanism underlying uncontrolled cellular prolifera-
tion, which leads to tumor formation. The spindle as-
sembly checkpoint plays important roles in mitosis by
preventing chromosome missegregation [34]. CDC20,
known as a key component of the spindle assembly
checkpoint proteins, is shown to drive mitosis from
metaphase to anaphase by activating a subunit of APC/
C [14]. Previous studies have demonstrated that knock-
down of CDC20 expression could lead to decreased cellular
proliferation in tumor cells [35, 36], and its overexpression
is associated with poor prognosis in many human cancers
[17–21]. In our observation from immunohistochemistry,
CDC20 was significantly up-regulated in RCC tissue in
comparison with normal kidney tissues. In addition, we
found that CYP1B1 knockdown in RCC cell lines leads to
altered expression of CDC20. Furthermore, there was a
trend that CDC20 expression was at a higher level in the
High CYP1B1 group as compared to the Low CYP1B1
group. Interestingly, the expression of Ki-67, an important
proliferative biomarker reflecting oncologic outcomes in-
cluding RCC [37, 38], was reported to be correlated with
CDC20 expression [21]. We found that MKI67 mRNA ex-
pression was also down-regulated in CYP1B1 siRNA-
treated RCC cells. Considering these findings, we believe
that CDC20 is closely associated with RCC tumorigenesis
and potentially regulated by CYP1B1.
Defects in apoptotic pathways promote tumor initi-
ation, progression and metastasis [39]. Apoptosis is
hence considered to be a major causative factor in
tumorigenesis. In this study, we clearly demonstrated
that down-regulation of CYP1B1 induced significantly
increased levels of apoptosis in Caki-1 cells. Also, we
sought to determine the genes associated with down-
Table 2 Cancer pathway-related and apoptosis-related genes
significantly altered in Caki-1
Refseq Symbol Description Fold
Change
Cancer pathway-related genes
NM_005994 DKC1 Dyskeratosis congenita 1, dyskerin 0.4918
NM_002982 OCLN Occludin 0.4816
NM_001147 FASLG Fas ligand (TNF superfamily,
member 6)
0.4107
NM_005983 MKI67 Antigen identified by monoclonal
antibody Ki-67
0.3950
NM_001315 LPL Lipoprotein lipase 0.3660
NM_001950 LIG4 Ligase IV, DNA, ATP-dependent 0.3572
NM_018975 CA9 Carbonic anhydrase IX 0.2484
NM_001002 CDC20 Cell division cycle 20 homolog (S.
cerevisiae)
0.1879
Apoptosis-related genes
NM_005427 TP73 Tumor protein p73 4.3079
NM_004049 BCL2A1 BCL2-related protein A1 2.2191
NM_000595 LTA Lymphotoxin alpha (TNF
superfamily, member 1)
2.1273
NM_004938 DAPK1 Death-associated protein kinase 1 2.0505
NM_016252 BIRC6 Baculoviral IAP repeat containing 6 0.5000
NM_003805 CRADD CASP2 and RIPK1 domain
containing adaptor with death
domain
0.4386
NM_003842 TNFRSF10B Tumor necrosis factor receptor
superfamily, member 10b
0.4368
NM_003844 TNFRSF10A Tumor necrosis factor receptor
superfamily, member 10a
0.4087
NM_001924 GADD45A Growth arrest and DNA-damage-
inducible, alpha
0.3821
NM_014430 CIDEB Cell death-inducing DFFA-like ef-
fector b
0.2975
NM_001066 TNFRSF1B Tumor necrosis factor receptor
superfamily, member 1B
0.2862
NM_003806 HRK Harakiri, BCL2 interacting protein
(contains only BH3 domain)
0.2360
NM_000594 TNF Tumor necrosis factor 0.2126
NM_001561 TNFRSF9 Tumor necrosis factor receptor
superfamily, member 9
0.1852
NM_001168 BIRC5 Baculoviral IAP repeat containing 5 0.1369
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regulated CYP1B1-mediated apoptosis and observed
overexpression of DAPK1 after CYP1B1 depletion in
RCC cell lines based on gene microarray analyses. Sev-
eral studies have shown that DAPK1 is a tumor-
suppressor gene and down-regulated in many types of
cancers [25–28]. In addition, an in vitro experiment re-
vealed that DAPK1 enzyme activity was reduced in RCC
[40]. We found that levels of DAPK1 protein were sig-
nificantly lower in RCC than normal tissue, and there
was an inverse correlation between protein levels of
CYP1B1 and DAPK1. These results indicate that DAPK1
may be regulated by CYP1B1 and the functional role of
DAPK1 in RCC is that of a tumor suppressor.
DAPK1 leads to p53 activation and apoptosis through
DAPK1 phosphorylation of tetrametric p53 on Ser20,
which is located within the transactivation domain that
binds p300 [41]. In addition, DAPK1 indirectly induces
p53 activation by activating the ARF tumor suppressor,
Fig. 4 Verification of cDNA microarray data by RT-PCR and Western blotting. a Among 9 down-regulated genes, 6 genes (DKC1, OCLN, MIK67,
LIG4, CDC20, BIRC5) were confirmed by real-time PCR using Taqman probe in Caki-1 cells. Of these 6 genes, CDC20 was down-regulated in both
Caki-1 and 769-P cells. *, P < 0.05. **, P < 0.01.***, P < 0.001. b Among 4 up-regulated genes, TP73 and DAPK1 were confirmed by real-time PCR and
only DAPK1 was down-regulated in both cell lines. *, P < 0.05. (C). Western immunoblotting analysis of DAPK1, LIG4 and CDC20 in control and
CYP1B1 transfected Caki-1 and 769-P cells. A positive correlation was found between protein levels and mRNA expression of DAPK1 and CDC20
in both cell lines. GAPDH was used as a loading control
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which inhibits MDM2, an inhibitor of p53 [23]. Thus, the
tumor suppressive mechanism of DAPK1 is tightly in-
volved in p53-dependent apoptosis. Also, it is well known
that mutations in p53 lose wild-type p53 tumor suppres-
sor activity and gain oncogenic ability. We hypothesize
that this may explain why restoration of DAPK1 through
CYP1B1 reduction did not induce an apoptotic effect in
769-P cells since they have a p53 mutation.
The expression of DAPK1 is thought to be down-
regulated by DNA promoter methylation and associ-
ated with poor prognosis in a variety of tumors
[25–28]. Promoter CpG hypermethylation appears to
be a common mechanism underlying gene silencing
and many tumor-related genes are also silenced by
DNA hypermethylation in RCC [42, 43]. The correl-
ation between methylation status of DAPK1 and
tumor progression in RCC has been demonstrated
[44, 45], although other studies have shown that its
expression may not be regulated by DNA promoter
methylation [40]. Further research is needed to clar-
ify the precise mechanism of DAPK1 restoration
through the depletion of CYP1B1.
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Fig. 5 Expression of CDC20 and DAPK1 and their correlation with CYP1B1 in clinical samples. a Representative immunostaining of CDC20, DAPK1
and CYP1B1 from matched samples including normal tissue, Low CYP1B1 RCC and High RCC tissues. Intracellular CDC20 accumulation was
positive in some cancer cells, whereas majority of the normal kidney cells were negative. Strong cytoplasmic staining of DAPK1 was more
common in the normal kidney tissues than in RCC samples. b CDC20 expression was significantly higher in RCC than normal kidney tissues. There
was a positive correlation between the expression of CDC20 and CYP1B1 in RCC, though it did not reach statistical significance. DAPK1
expression was significantly down-regulated in RCC as compared to normal tissues. The expression level of DAPK1 was also significantly correlated
with Low and High CYP1B1 expression in RCC. *, P < 0.05. **, P < 0.01.***, P < 0.001
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Conclusions
In summary, our study demonstrates that CYP1B1 deple-
tion reduces tumorigenesis in RCC cell lines. In clinical
RCC samples, CYP1B1 expression seemed to be associated
with unfavorable prognostic factors. CYP1B1 may promote
RCC development by inducing CDC20 expression and
inhibiting apoptosis through the down-regulation of
DAPK1. In view of these results, we conclude that CYP1B1
may be an attractive target for designing improved diag-
nostic and therapeutic strategies for RCC.
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